DURHAM, N.C.and SEATTLE, Jan. 28, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at ...
Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue ...
This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...
1don MSN
Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...
Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.
Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...
Australian cancer researchers are the first to establish a next-generation gene-editing tool for modelling and interrogating human disease.
A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...
MGX’s gene editing uses metagenomics and AI to build a “toolbox” of nucleases and base editors. Currently, their main application seems to be heading toward Hemophilia A, but even this IP is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback